Diagnosis of inherited von Willebrand disease: a clinical perspective by A.B. Federici
Diagnosis of Inherited von Willebrand
Disease: A Clinical Perspective
Augusto B. Federici, M.D.1
ABSTRACT
von Willebrand disease (VWD) is the most frequent inherited disorder of hemo-
stasis and is due to quantitative (types 1 and 3) or qualitative (type 2) defects of von
Willebrand factor (VWF). Due to the large heterogeneity of VWF defects and to the
external variables inﬂuencing VWF levels in the circulation, VWDdiagnosis can be difﬁcult,
especially in relatively mild forms. Three criteria should be always satisﬁed for a correct
VWD diagnosis: (1) a positive bleeding history since childhood; (2) reduced levels of VWF
activity in plasma; and (3) autosomal dominant or recessive inheritance patterns within the
family (in most cases). According to clinical prospective studies, a bleeding history in VWD
patients should be derived from a detailed questionnaire, with calculated bleeding scores.
The ristocetin cofactor activity is the most useful test for VWD screening in the general
population because it reproduces in vitro the ﬁrst VWF interactions with its platelet receptor;
however other assays are required to identify and classify VWD types. The current
classiﬁcation (types 1, 2A, 2B, 2M, 2N, and 3) is important to understand the basic
mechanisms of VWF defects, to determine the risk of bleeding, and to select the best
therapeutic approach.Molecular screening can be important to conﬁrm phenotypic diagnosis
for tracking VWF defects within families. Compared with hemophilia, most VWD patients
show relatively mild bleeding symptoms. Therefore, prenatal diagnosis is required only for
women already known to be carriers of VWD type 3.No spontaneous bleedings usually occur
at birth in severe type 3 VWD.Neonatal diagnosis of VWD should always be compared with
other affected members within the same family. Given that young children with VWD type
3 might carry deletions of VWF gene that predispose to the alloantibodies to VWF, every
new child with VWD type 3 should be investigated intensively for VWF gene deletions
before starting extensive therapy with exogenous VWF concentrates.
KEYWORDS: Inherited von Willebrand disease, von Willebrand factor, bleeding score,
ristocetin cofactor activity, genetic and molecular diagnosis
When Erik von Willebrand in 1926 described a
novel bleeding disorder in a large family from Foglo on
the islands of Aaland in the Gulf of Bothnia, he provided
an impressive and exhaustive description of its clinical
and genetic features. Unlike hemophilia, the epitome of
inherited bleeding disorders, both sexes were affected,
and mucosal bleeding was the dominant symptom.
Prolonged bleeding times (BTs) with normal platelet
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counts was the most important laboratory abnormality,
and a functional disorder of the platelets associated with
systemic lesion of the vessel wall was suggested as a
possible cause of the disorder. However, he called the
disease ‘‘hereditary pseudohaemophilia.’’ To complicate
the issue further, some authors subsequently called the
disorder ‘‘vascular hemophilia.’’
Only in the 1950s was it demonstrated that the
prolonged BTs in these patients was associated with
reduced factor (F) VIII, but we had to wait until the
1970s to clarify that the deﬁciency of a new factor, called
von Willebrand factor (VWF) and different from FVIII,
was actually responsible for the disease. Surprisingly, the
reduction of this factor caused low FVIII levels, pointing
to the close relationship between the two proteins. In the
1980s, the cloning of the VWF gene set the basis for
unraveling the molecular causes of the disorder.
The history of von Willebrand disease (VWD)
has been the subject of a review.1 In this review, I discuss
the progress and the current problems of VWD diag-
nosis, 80 years after the original description by Erik von
Willebrand.
STRUCTURE—FUNCTION OF VWF AND ITS
CHANGES DURING EARLY CHILDHOOD
VWF is synthesized by endothelial cells and megakar-
yocytes.2 The gene coding for VWF has been cloned and
located at chromosome 12p13.2. It is a large gene
composed of 178 kilobases and containing 52 exons.
A noncoding, partial, highly homologous pseudogene
has been identiﬁed in chromosome 22. The pseudogene
spans the gene sequence from exon 23 to 34.3 The
primary product of the VWF gene is a protein with
2813 amino acids made of a signal peptide of 22 amino
acids (also called a prepeptide), a large propeptide of 741
amino acids, and a mature VWF molecule containing
2050 amino acids. In keeping with a recently proposed
nomenclature,4 numbering starts from the ﬁrst amino
acid of the signal peptide, so 764 is the ﬁrst amino acid of
the mature protein. Different protein regions, corre-
sponding to four types of repeated domains (D1, D2,
D0, D3, A1, A2, A3, D4, B, C1, C2) of cDNA, are
responsible for the different binding functions of the
molecule (Fig. 1). Mature VWF is the result of ordered
intracellular processing, leading to the storage and/or
secretion of a heterogeneous array of multimeric, multi-
domain glycoproteins, referred to as VWF.
VWF has two major functions in hemostasis.
First, it is essential for platelet–subendothelium adhe-
sion and platelet-to-platelet interactions, as well as
platelet aggregation in vessels in which rapid blood
ﬂow results in elevated shear stress, a function partially
explored in vivo by measuring the BTs. Adhesion is
promoted by the interaction of a region of the A1
domain of VWF with glycoprotein (GP) Iba on the
Figure 1 Schematic representation of the vonWillebrand factor (VWF) gene located in chromosome 12 together with the pseudogene
in chromosome 22. The main exons are indicated with the number of base pairs from 50 to 30 (above). DNA domain structure and pre-pro-
VWF polypeptide: the pre-pro-VWF is indicated with amino acids numbered from the amino- (aa 1) to carboxy-terminal portions (aa 2813)
of VWF. Note the important CK and D3 domains for formation of VWF dimers and multimers (below). The native mature subunit of VWF,
after the cleaving of the pre-pro VWF, is described with its functional domains: the VWF binding sites for factor (F) VIII (D0 and D3),
glycoprotein Ib (GPIb), botrocetin, heparin, sulfatide, collagen (A1), collagen (A3), and the RGD sequence for binding to aIIbb3.
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platelet membrane. It is believed that high shear stress
activates the A1 domain of the collagen-bound VWF by
stretching VWF multimers into their ﬁlamentous form.
Furthermore, GPIba and VWF are also necessary for
platelet-to-platelet interactions.2 The interaction be-
tween GPIba and VWF can be mimicked in platelet-
rich plasma by addition of the antibiotic ristocetin,
which promotes the binding of VWF to GPIba of fresh
or formalin-ﬁxed platelets. Aggregation of platelets
within the growing hemostatic plug is promoted by the
interaction with a second receptor on platelets, GPIIb-
IIIa (or integrin aIIbb3) which, once activated, binds to
VWF and ﬁbrinogen, recruiting more platelets into a
stable plug. Both of these binding activities of VWF are
highly expressed in the largest VWF multimers.
Second, VWF is the speciﬁc carrier of FVIII in
plasma. VWF protects FVIII from proteolytic degrada-
tion, prolonging its half-life in the circulation and efﬁ-
ciently localizing it at the site of vascular injury. Each
VWF monomer has one binding domain, located in the
ﬁrst 272 amino acids of the mature subunit (D0 domain),
which can bind one FVIII molecule, in vivo; however,
only 1 to 2% of available monomers are occupied by
FVIII.5 Therefore, any change in plasma VWF levels is
usually associated with a concordant change in FVIII
plasma concentrations. The correct nomenclature with
abbreviations of the different FVIII/VWF activities, as
approved by the Scientiﬁc Standardization Committees,
Sub-Committee on VWF, of the International Society of
Thrombosis and Haemostasis (ISTH-SSC on VWF),
are summarized in Table 1.6
The mature native VWF circulates in plasma of
normal individuals at a concentration of 5 to 15 mg/mL:
subjects with blood group O show lower plasma levels of
VWF than those with blood group non-O.7 During fetal
growth, VWF retains ultralarge molecular weight forms
and plasma levels of VWF are higher in the newborn
than in children: only after 6 months from birth, chil-
dren show their actual levels of VWF and FVIII.8,9
These data can explain why neonates with severe forms
of VWD do not usually bleed, but should also be taken
into consideration when VWD diagnosis is suspected in
young children during their ﬁrst 6 to 8 months of life.
Classiﬁcation of VWD
The revised classiﬁcation of VWD identiﬁes two major
categories, characterized by quantitative (types 1 and 3)
or qualitative (type 2) VWF defects.10 A partial quanti-
tative deﬁciency of VWF in plasma and/or platelets
identiﬁes type 1, whereas type 3 is marked by the total
absence or only trace amounts of VWF in plasma and
platelets. Type 1 is easily distinguished from type 3 by
the milder VWF deﬁciency (usually in the range of 10 to
40 U/dL), the autosomal dominant inheritance pattern,
and the presence of milder bleeding symptoms.11
Four type 2 VWD subtypes have been identiﬁed,
reﬂecting different pathophysiologic mechanisms. Type
2A and 2B VWD are marked by the absence of high
molecular weight VWFmultimers in plasma; in type 2B,
there is increased afﬁnity for platelet GPIb-IX-V com-
plex (GPIba). The identiﬁcation of qualitatively abnor-
mal variants with decreased platelet-dependent function
and the presence of normal multimers on gel electro-
phoresis has led the addition of a new subtype, called
2M. If this deﬁnition is followed and more stringent
criteria are applied to VWD diagnosis, many cases
previously identiﬁed as type 1 should now be classiﬁed
as type 2M because they are caused by single missense
mutations affecting VWF function but not its multi-
meric structure and assembly. Furthermore, type 2N
(Normandy) also shows a full array of multimers because
the defect lies in the N-terminal region of the VWF
molecule where the binding domain for factor VIII
resides. This type is phenotypically identiﬁed only by
an abnormal FVIII/VWF binding test: in fact, this test is
always normal in mild hemophiliacs or carriers of hemo-
philia A.12 The current classiﬁcation of VWD, summar-
ized in Table 2, was proposed by Sadler10 in 1994 on
behalf of the ISTH-SSC on VWF. A working party,
composed by experts in the ﬁeld, has the duty to prepare
the updated classiﬁcation of VWD within 2006.
PREVALENCE AND FREQUENCY OF
DIFFERENT VWD TYPES
VWD is the most frequent inherited bleeding disorder,
with a prevalence of up to 1% in certain geographic areas
according to population studies.11 On the other hand,
prevalence based on the number of patients registered at
specialized centers ranges from four to 10 cases/100,000
inhabitants: symptomatic VWD patients requiring spe-
ciﬁc treatment are 50 to 100 per million.11
In the past, type 1 was reported as the most
frequent form of VWD (Table 3). A recent retrospective
Table 1 Recommended Nomenclature of Factor
VIII/von Willebrand Factor Complex
Components
Recommended
Nomenclature
Factor VIII
Protein FVIII
Antigen FVIII:Ag
Function FVIII:C
von Willebrand factor
Mature protein VWF
Antigen VWF:Ag
Ristocetin cofactor activity VWF:RCo
Collagen-binding capacity VWF:CB
Factor VIII binding capacity VWF:FVIIIB
Table derived from Mazurier et al.6
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study based on reappraisal of type 1 diagnoses after
10 years (1994 versus 2004) in 1234 VWD patients
followed by 16 Italian hemophilia centers, found that
VWD type 1 was present in only 671 (54%) of 1234
patients, because most of previously diagnosed VWD
type 1 patients were rediagnosed as type 2 according
to their discrepant VWF activities (VWF:ristocetin
cofactor activity [RCo]/antigen [Ag] ratio < 0.7). Age
distribution of the 1234 Italian VWD patients was 5 to
86 years, with 267 (22%) of 1234 cases age younger than
20 years.13,14
GENERAL APPROACH TO THE DIAGNOSIS
OF VWD
Three main criteria should be satisﬁed for a correct VWD
diagnosis: (1) positive bleeding history since childhood;
(2) reduced levels of VWF activity; and (3) autosomal
dominant or recessive inheritance patterns, in most cases.
Given that de novo mutations of the VWF gene cannot be
excluded in a patient without any affected members
within the family, a correct diagnosis of VWD should
always require at least two criteria, namely, reduced levels
of VWF activity and a signiﬁcant bleeding history since
childhood. Therefore, the analysis of the patient’s bleed-
ing history plays a major role in the decision made by the
hematologists for the ﬁnal diagnosis of VWD, especially
in patients with borderline levels of VWF activity, close
to those observed in normal individuals.
STANDARDIZED CRITERIA FOR
EVALUATION OF THE BLEEDING HISTORY:
A BLEEDING SCORE
Several attempts have been made recently by clinicians,
experts in VWD, to evaluate the sensitivity and speciﬁc-
ity of bleeding symptoms, which are important especially
in the mild cases of type 1 VWD, with VWF:RCo levels
> 30 U/dL. In a multicenter study about the clinical
presentation of type 1 VWD in obligatory carriers, it has
been shown that menorrhagia and epistaxis are not good
predictors of type 1 VWD, whereas cutaneous bleeding
and bleeding after dental extractions should be consid-
ered the most sensitive symptoms.15 Therefore, a speciﬁc
bleeding score has been proposed for general use in the
diagnosis of VWD (Table 4). This bleeding score has
been tested in affected and nonaffected members of 154
VWD families enrolled prospectively in a large Euro-
pean study, as well as in 200 normal individuals.16
CLINICAL FEATURES AND BLEEDING
SYMPTOMS IN DIFFERENT VWD TYPES
The clinical expression of VWD is usually mild in most
type 1 disease; severity increases in types 2 and 3 disease.
In general, the severity of bleeding correlates with the
degree of the reduction of VWF:RCo and FVIII:coa-
gulant activity (C) activities, but not with the magnitude
of BT prolongation or with the patient’s ABO blood
type. Mucocutaneous bleeding (epistaxis, menorrhagia)
is a typical manifestation of the disease and may even
affect the quality of life. VWD may be highly prevalent
in patients with isolated menorrhagia.11 Women with
VWD may require treatment with antiﬁbrinolytics, iron
supplementation, or an estrogen/progesterone pills to
control heavy menses. Bleeding after dental extraction is
the most frequent postoperative bleeding manifestation.
Given that FVIII:C is usually only slightly reduced,
manifestations of a severe coagulation defect (hemarth-
rosis, deep muscle hematoma) are rare in type 1 VWD
and are mainly posttraumatic. In type 1 VWD bleeding
after delivery is rare because FVIII/VWF levels tend to
become normal at the end of pregnancy. Postoperative
bleeding may not occur even in more severely affected
type 1 VWD patients, but in type 3 VWD prophylaxis is
always required. To date, only a few detailed descriptions
of symptoms in VWD patients have been provided,17,18
but only one study took into account the differentiation
Table 2 Classification of von Willebrand Disease
Quantitative deﬁciency of VWF
Type 1: Partial quantitative deﬁciency of VWF
Type 3: Virtually complete deﬁciency of VWF
Qualitative deﬁciency of VWF
Type 2: Qualitative deﬁciency of VWF
(A) Type 2A: Qualitative variants with decreased
platelet-dependent function associated with the absence
of high-molecular-weight VWF multimers
(B) Type 2B: Qualitative variants with increased afﬁnity for
platelet GPIba
(C) Type 2M: Qualitative variants with decreased
platelet-dependent function not caused by the absence
of high-molecular-weight VWF multimers
(D) Type 2N: Qualitative variants with markedly decreased
afﬁnity for factor VIII
VWF, von Willebrand factor; GPIba, glycoprotein Iba.
(From Sadler JE. A revised classification of von Willebrand disease.
Thromb Haemost 1994;71:520–523.)
Table 3 Frequency of von Willebrand Disease Types
Authors
Number of
Patients
Type 1
(%)
Type 2
(%)
Type 3
(%)
Tuddenham 134 75 19 6
Lenk et al 111 76 12 12
Hoyer et al 116 71 23 6
Awidi 65 59 30 11
Berliner et al 60 62 9 29
Federici et al 1234 54 40 6
(From Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von
Willebrand’s disease in the year 2003: towards the complete
identification of gene defects for correct diagnosis and treatment.
Haematologica 2003;88:94–108.)
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according to the VWD types.13,14 The relative frequency
of bleeding symptoms in three large series of patients
with VWD diagnosed at specialized centers is reported
and listed in Table 5.
LABORATORY TESTING TO DIAGNOSE
VWD TYPES: A FLOW CHART
Once it is suspected that a patient has VWD because of a
positive bleeding history since childhood, a set of differ-
ent laboratory tests should be performed to make a
deﬁnitive diagnosis of the VWD type. Due to the large
heterogeneity of VWF defects and to the external vari-
ables inﬂuencing VWF levels in the circulation, the
diagnosis of VWD, particularly type 1, may require
several laboratory tests to be repeated at different occa-
sions (Table 6). The BT is usually prolonged, although it
may be normal in patients with mild forms of VWD such
as those with type 1 and normal platelet VWF content.19
Differential diagnosis of VWD types can be done
by using these laboratory tests, following the ﬂow chart
already proposed by the guidelines for diagnosis and
treatment of VWD in Italy (Fig. 2). Type 3 VWD can
be diagnosed in case of unmeasurable VWF:Ag levels.
A proportionate reduction of both VWF:Ag and
VWF:RCo with a RCo/Ag ratio > 0.7 suggests type 1
VWD. If the VWF:RCo/Ag ratio is < 0.7, type 2 is
diagnosed. Type 2B VWD can be identiﬁed in the
presence of an enhanced ristocetin-induced platelet ag-
glutination (RIPA;< 0.8 mg/mL), whereas types 2A and
2M cause low RIPA (> 1.2 mg/mL). Multimeric analysis
in plasma is necessary to distinguish between type 2A
VWD (lack of the largest and intermediate multimers)
and type 2M VWD (all the multimers present). Type 2N
VWD can be suspected in the presence of discrepant
values for FVIII and VWF:Ag (ratio < 1) and diagnosis
should be conﬁrmed by the speciﬁc test of VWF:FVIIIC.
In type 1 VWD the ratio between FVIII and VWF:Ag is
always  1 and the severity of type 1 VWD phenotype
usually can be evaluated from platelet VWF measure-
ments.19
Additional tests for VWD diagnosis include the
closure time (CT) and assays of VWF activity based on
Table 6 Clinical and Laboratory Parameters Used for
von Willebrand Disease (VWD) Diagnosis
Patients at risk for VWD
Clinical history: lifelong mucocutaneous and postoperative
bleeding; symptoms are sometimes present in other family
members (bleeding score)
Screening tests: prolonged bleeding time (may be normal);
normal platelet counts; prolonged PTT (may be normal)
Diagnosis and deﬁnition of VWD*
VWF antigen [a]
VWF:ristocetin cofactor activity [b]
Factor VIII [c]
VWF multimeric structure on low-resolution gels [e]
Diagnosis of VWD types*
RIPA [d]
VWF multimeric structure on high-resolution gels [e]
Platelet VWF content [f]
Factor VIII binding assay [g]
*For the use of these tests, see the diagnostic flow chart reported in
Fig. 2 and also by Federici et al.13
PTT, partial thromboplastin time; VWF, von Willebrand factor; RIPA,
ristocetin-induced platelet agglutination.
Table 5 Incidence (%) of Bleeding Symptoms in Patients with vonWillebrand Disease (VWD) and in Normal Subjects
Symptoms
Iranian VWD Italian VWD (n¼1234)* Scandinavian
Type 3
(n¼348)
Type 1
(n¼671)
Type 2
(n¼ 497)
Type 3
(n¼ 66)
VWD
(n¼ 264)
Normal Subjects
(n¼500)
Epistaxis 77 61 63 66 62 5
Menorrhagia 69 32 32 56 60 25
Postextraction bleeding 70 31 39 53 51 5
Hematomas NR 13 14 33 49 12
Bleeding from minor wounds NR 36 40 50 36 0.2
Gum bleeding NR 31 35 56 35 7
Postsurgical bleeding 41 20 23 41 28 1
Postpartum bleeding 15 17 18 26 23 19
Gastrointestinal bleeding 20 5 8 20 14 1
Joint bleeding 37 3 4 45 8 0
Hematuria 1 2 5 12 7 1
Cerebral bleeding NR 1 2 9 NR 0
*Bleeding symptoms in Italian patients have been recalculated recently according to the updated results of the Italian Registry of VWD and
therefore are different from those reported previously.13,14
(From Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of VWD in Italy. Haemophilia 2002;8:607–621;
Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004;10:169–176; von Silwer J. Willebrand’s disease in Sweden. Acta
Paediatr Scand 1973;238:1–159; Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement
therapy in 348 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000;111:1223–1229.)
NR, not reported.
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collagen-binding activity (CB). Evaluation of CT with
the Platelet Function Analyser (PFA-100; Dade-
Behring, Marburg, Germany) gives a rapid and simple
measure of VWF-dependent platelet function at high
shear stress: the analysis can be performed in whole
blood and therefore has been proposed instead of BT
in children. This system is sensitive and reproducible for
VWD screening, but is not always speciﬁc and must be
performed always together with other VWF tests.11
Assays are also available for VWF:CB and the ratio of
VWF:CB to VWF:Ag appears useful for distinguishing
types 1 and 2: however, results can vary according to the
type of collagen sources.20 In Italy, we have introduced
VWF:CB in our panel of assays together with
VWF:RCo since 1998, and VWF:CB has been proven
to be a very useful additional test to discriminate between
types 2A and 2M VWD. 21
CLINICAL EXPRESSION OF VWF DEFECTS:
SEVERE, MODERATE, AND MILD FORMS
OF VWD
Type 3 is always severe by deﬁnition because it is
characterized by unmeasurable VWF level in both plasma
and platelets and by low amounts of FVIII:C (< 20 U/
dL). Conversely, types 1 and 2 VWD are very heteroge-
neous and their clinical presentation is related strictly to
the circulating levels of VWF functional activities, meas-
ured as VWF:RCo. In the last 5 years, an international
prospective study on the use of desmopressin in severe
forms of VWD has been performed by ﬁve European
hemophilia centers in the framework of the 5th Project
sponsored by the European Community, and the results
have been published.22 For the ﬁrst time, the Steering
Committee of this study made an attempt to deﬁne
patients with severe VWD forms, using levels of
FVIII/VWF activities as criteria for severity. Patients
with severe VWD were deﬁned as those who were
characterized by a lifelong history of bleeding (including
at least two episodes of blood loss severe enough to
require replacement therapy) and by the presence of
at least one of the following laboratory abnormalities:
BTs > 15 minutes, VWF:RCo < 10 IU/dL, FVIII:C
< 20 IU/dL.22 Similar criteria have been used by the
Steering Committee of the Italian National Registry on
VWD to evaluate retrospective data on 1234 VWD
patients collected from 16 hemophilia centers on behalf
of the Italian Association of Hemophilia Centers.14
Therefore, a mild form of VWD can be diagnosed
when patients show a mild personal and family bleed-
ing history with levels of VWF:RCo 10 to 40 U/dL
and/or FVIII:C 20 to 50 U/dL, with or without
prolonged BT. Conversely, the diagnosis of VWD
can be considered for patients with values close to
normal ranges. The deﬁnition of disease versus reduced
levels of normal VWF is difﬁcult in the absence of
bleeding history in other members of the family, as
reported recently.23,24 A pictorial representation of the
Figure 2 Flow chart proposed in diagnosis of different von Willebrand disease (VWD) types (see description in the text).
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different degrees of VWD severity according to levels
of FVIII/VWF activities is shown in Fig. 3.
PATTERNS OF INHERITANCE
The inheritance pattern of VWD type 3 is autosomal
recessive. In type 2 VWD patients, the pattern of
inheritance is mainly autosomal dominant, even though
rare cases with recessive pattern have been reported.11
The inheritance of the mild type 1 VWD is usually
autosomal dominant, with variable phenotype and
penetrance. Despite its high prevalence, the precise
genetic cause of type 1 VWD is still elusive in most
cases, especially in those with a mild phenotype. In type
1 VWD, in fact, several genetic and nongenetic factors
are likely to contribute to the wide variability of the
clinical and laboratory phenotype. About 60% of the
variations in VWF plasma are due to genetic factors,
with ABO group accounting for only 30%. In type O
subjects the VWF level is 25 to 35% lower than in non-
O individuals.7 Additional factors other than the VWF
gene, such as platelet polymorphisms, have been pro-
posed to modify the bleeding tendency of type 1 VWD,
as reported.25
MOLECULAR AND PRENATAL
DIAGNOSIS OF VWD
Cloning the VWF gene has allowed the identiﬁcation of
several suitable restriction fragment length polymor-
phisms (RFLP), which demonstrate the cosegregation of
VWD phenotype with haplotype-speciﬁc RFLP patterns
in family members of different kindred with VWD.11
Understanding of the crucial segments of VWF involved
in the interaction with GPIba initially prompted the
fruitful search for mutations in exon 28 of the VWF
gene,which encodes for theA1 andA2domains ofmature
VWF, as shown in Fig. 1 (review by Castaman et al11).
The search for mutations has been extended to additional
VWF exons encoding for the other functional domains
of VWF. The most frequent mutations reported in
types 2A, 2B, 2M, and 2N are listed in Table 7 according
to the speciﬁc VWF domains and are currently updated
on the Web site organized on behalf of the
ISTH-SSC on VWF (www.shef.ac.uk/vwf).
Most type 2A cases are due to missense mutations
in the A1 domain, with R1597W or Q or Y and S1506L
accounting for 60%.26 The majority of type 2B cases
are due to missense mutations in the A1 domain; 90%
are caused by R1306W, R1308C, V1316M, and
R1341Q mutations (Table 7). A few heterogeneous
mutations are responsible for type 2M cases and are also
located within the A1 domain. Therefore, most muta-
tions are expressed and the mutated recombinant VWF
has been compared with others found within the same
domain.27 A recurrent mutation in type 2M Vicenza
has been reported recently in families from Europe
(R1205H), associated with a second nucleotide change
(M740I) and identiﬁed exclusively in some families
from the Vicenza area.28,29 Missense mutations in the
Figure 3 Pictorial representation of the three different degrees of vonWillebrand disease (VWD) severity according to levels of factor
(F) VIII/vonWillebrand factor (VWF) activities: severe, moderate, andmild VWD forms. In the upper part of the pyramid, the most severe
VWD forms (types 3, 2A, 2M, 1) are included with levels of VWF:RCo <10 U/dL and/or FVIII:coagulant activity (C) <20 U/dL. The
moderate VWD forms (types 1, 2B, 2M, 2N) with levels of VWF:RCo 10 to 30 U/dL and/or FVIII:C 20 to 40 U/dL and the mild VWF forms
(VWF:RCo 30 to 50 U/dL and/or FVIII:C 40 to 60 U/dL) are described in the middle portion and in the base of the pyramid. Due to the
physiological changes of VWF and of the variability of the assays, a very mild VWD form with values of VWF:RCo and/or FVIII:C > 40 U/
dL can be diagnosed only when these low-borderline levels of FVIII/VWF activities are associated with personal and family bleeding
history. Therefore, the lower the levels of VWF:RCo or FVIII:C, the higher is the probability of a current VWD diagnosis: in this sense, the
severe VWD forms might represent the tip of the iceberg of a large number of moderate and mild VWF defects.
562 SEMINARS IN THROMBOSIS AND HEMOSTASIS/VOLUME 32, NUMBER 6 2006
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 d
eg
li S
tu
di
 d
i M
ila
no
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
FVIII-binding domain at the amino-terminal portion
of VWF are responsible for type 2N (reviewed by
Mazurier et al12).
Despite its high prevalence, the precise genetic
cause of type 1 VWD is still elusive in most cases,
especially in those with a mild phenotype. The molecular
defects are distributed within the entire VWF gene.
More information about molecular diagnosis of VWD
type 1 will be available as soon as the data of the
European project entitled Molecular and Clinical
Markers for Diagnosis and Management of Type 1
VWD are published later in 2006.
In type 3 VWD, partial or total gene deletions
have been reported initially (reviewed by Eiken-
boom30). Notably, homozygous states for gene dele-
tion may be associated with the appearance of
alloantibodies against VWF, which may render re-
placement therapy ineffective and stimulate anaphy-
lactic reactions to treatment.11 Gene defects of type 3
VWD patients from different populations have now
been studied, but there was no founder effect and
mutations were distributed throughout the entire
VWF gene.31
Compared with hemophilia, most VWD pa-
tients show relatively mild bleeding symptoms.
Therefore, prenatal diagnosis is required mainly if
parents are already known to be carriers of VWD
type 3, with gene defects identiﬁed in their ﬁrst
affected child. Neonatal diagnosis can be performed
in children born from parents with VWF defects
already characterized, but phenotypic diagnosis of
VWD should always be conﬁrmed later in the child’s
life and compared with the other affected members
within the same family. Given that young children
with VWD type 3 might carry deletions of VWF
gene that predispose them to the alloantibodies to
VWF, every new child with VWD type 3 should be
investigated intensively by searching deletions using
Southern blot analysis (as reported by Shelton-Inloes
et al32) before extensive therapy with exogenous VWF
concentrates is started.
CONCLUSIONS
VWD is the most frequent inherited bleeding disorder.
The prevalence of clinically relevant VWD has not been
Table 7 Most Frequent Mutations in Types 2A, 2B, 2M, and 2N According to VWF Domains
Localization of VWF Defects VWD Types VWF Mutations Associated with Speciﬁc Types
D2 domain Type 2A (formerly IIC) F404insNP - R436del6 - N528S - G550R
C623W - A625insG
D0–D3 domains Type 2N R782W - G785E - E787K - C788R
C788Y - T791M - Y795C - M800V
R816W - R816Q - H817Q - R854Q
R854W - C858F - D879N - Q1053H
C1060R - C1225G
D3 domain Type 2M (formerly 1 Vicenza) R1205H - Y1146C
Type 2A (formerly IIE) C1143Y - C1173R
A1 domain Type 2B (formerly IIB) P1266L - H1268D - C1272G - C1272R
M1304insM- R1306Q - R1306L - R1306W
R1308C - R1308P - I1309V - S1310F
W1313C - V1314F - V1314L - V1316M
P1337L - R1341L - R1341Q - R1341W
L1460V - A1461V
Type 2M G1324S - G1324A - E1359K - F1369I
I1425F - Q1191del1- K1408delK
Type2M/2A L1276P - R1374C - R1374H -C1458Y
R1374R
A2 domain Type 2A (formerly IIA) G1505E - G1505R - S1506L - F1514C
K1518E - L1540P - S1543F - Q1556R
L1562P - R1597G - R1597Q - R1597W
V1604F - V1607D - V1609R - P1627H
I1628T - G1629R - V1630F - E1638K
L1639P - P1648S - L1657I - V1665E
G1672R
CK domain Type 2A (formerly IID) C2773R
For an updated list of VWF mutations according to VWD types, refer to the Web site www.shef.ac.uk/vwf.
VWF, von Willebrand factor; VWD, von Willebrand disease.
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estimated directly in the population, but a ﬁgure of
100/million, similar to that of hemophilia A, is widely
accepted. A detailed collection of the bleeding history
with calculation of the bleeding score is essential to
identify patients with VWD in the presence of mild
defects of VWF by laboratory testing. The phenotypic
diagnosis is still the most accessible approach to a correct
VWD diagnosis, taking into account the difﬁculties and
costs of molecular diagnosis. However, molecular diag-
nosis can be useful to conﬁrm and track speciﬁc VWF
defects within VWD families.
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